Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)

被引：1
作者：
Motzer, Robert J.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 21期
关键词：
D O I：
10.1200/JCO.23.00901
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3767 / 3767
页数：1
相关论文
共 50 条
[41]   Efficacy and safety of nivolumab plus ipilimumab (N plus I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. [J].
Tannir, Nizar M. ;
Signoretti, Sabina ;
Choueiri, Toni K. ;
McDermott, David F. ;
Motzer, Robert J. ;
George, Saby ;
Powles, Thomas ;
Donskov, Frede ;
Tykodi, Scott S. ;
Pal, Sumanta K. ;
Gupta, Saurabh ;
Lee, Chung-Wei ;
McHenry, M. Brent ;
Rini, Brian I. .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[42]   Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101) [J].
Choueiri, Toni K. ;
Rini, Brian I. ;
Larkin, James M. G. ;
Bjarnason, Georg A. ;
Gravis, Gwenaelle ;
Gurney, Howard ;
Lee, Jae-Lyun ;
Keizman, Daniel ;
Haanen, John B. A. G. ;
Tomita, Yoshihiko ;
Uemura, Hirotsugu ;
Albiges, Laurence ;
Schmidinger, Manuela ;
Atkins, Michael B. ;
Mariani, Mariangela ;
Shnaidman, Michael ;
Di Pietro, Alessandra ;
Motzer, Robert J. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[43]   Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC). [J].
Motzer, Robert J. ;
Choueiri, Toni K. ;
McDermott, David F. ;
Powles, Thomas ;
Yao, Jin ;
Ammar, Ron ;
Papillon-Cavanagh, Simon ;
Saggi, Shruti S. ;
McHenry, Brent M. ;
Ross-Macdonald, Petra ;
Wind-Rotolo, Megan .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[44]   Long-term follow-up on overall survival and independent review of response in CheckMate 214: first-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) [J].
Grimm, M. -O. ;
Tannir, N. ;
McDermott, D. ;
Escudier, B. ;
Hammers, H. ;
Aren Frontera, O. ;
Plimack, E. ;
Barthelemy, P. ;
Neiman, V. ;
George, S. ;
Porta, C. ;
Powles, T. ;
Donskov, F. ;
Amin, A. ;
Tykodi, S. ;
Tomita, Y. ;
Rini, B. ;
McHenry, M. B. ;
Saggi, S. S. ;
Motzer, R. .
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) :208-208
[45]   Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) [J].
Tannir, Nizar M. ;
McDermott, David F. ;
Escudier, Bernard ;
Hammers, Hans J. ;
Aren, Osvaldo Rudy ;
Plimack, Elizabeth R. ;
Barthelemy, Philippe ;
Neiman, Victoria ;
George, Saby ;
Porta, Camillo ;
Powles, Thomas ;
Donskov, Frede ;
Grimm, Marc-Oliver ;
Amin, Asim ;
Tykodi, Scott S. ;
Tomita, Yoshihiko ;
Rini, Brian I. ;
McHenry, M. Brent ;
Saggi, Shruti Shally ;
Motzer, Robert J. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[46]   Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC) [J].
Motzer, R. J. ;
Choueiri, T. ;
Larkin, J. ;
Albiges, L. ;
Haanen, J. B. ;
Schmidinger, M. ;
Atkins, M. B. ;
Mariani, M. ;
Shnaidman, M. ;
Di Pietro, A. ;
Rini, B. I. .
ANNALS OF ONCOLOGY, 2016, 27
[47]   Dual immune checkpoint inhibition in metastatic renal cell carcinoma Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial [J].
Schmidinger, M. ;
Shariat, S. F. ;
Fajkovic, H. .
ESMO OPEN, 2021, 6 (01)
[48]   Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial [J].
Tannir, N. M. ;
Albiges, L. ;
Mcdermott, D. F. ;
Burotto, M. ;
Choueiri, T. K. ;
Hammers, H. J. ;
Barthelemy, P. ;
Plimack, E. R. ;
Portat, C. ;
George, S. ;
Donskov, F. ;
Atkins, M. B. ;
Gurney, H. ;
Kollmannsberger, C. K. ;
Grimm, M. -o. ;
Barrios, C. ;
Tomita, Y. ;
Castellano, D. ;
Gruenwald, V. ;
Rini, B. I. ;
Jiang, R. ;
Desilva, H. ;
Fedorov, V. ;
Lee, C. -w. ;
Motzer, R. J. .
ANNALS OF ONCOLOGY, 2024, 35 (11) :1026-1038
[49]   A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER). [J].
Choueiri, Toni K. ;
Apolo, Andrea B. ;
Powles, Thomas ;
Escudier, Bernard ;
Aren, Osvaldo Rudy ;
Shah, Amishi ;
Kessler, Elizabeth Riley ;
Hsieh, James J. ;
Zhang, Joshua ;
Simsek, Burcin ;
Scheffold, Christian ;
Motzer, Robert J. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[50]   Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. [J].
Powles, Thomas ;
Choueiri, Toni K. ;
Burotto, Mauricio ;
Escudier, Bernard ;
Bourlon, Maria Teresa ;
Shah, Amishi Yogesh ;
Suarez, Cristina ;
Hamzaj, Alketa ;
Porta, Camillo ;
Hocking, Christopher ;
Kessler, Elizabeth R. ;
Gurney, Howard ;
Tomita, Yoshihiko ;
Bedke, Jens ;
Zhang, Joshua ;
Simsek, Burcin ;
Scheffold, Christian ;
Apolo, Andrea B. ;
Motzer, Robert J. .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345